The BC that has improved its prognosis the most in the last few years is the one overexpressing HER2, which constitutes 20% of invasive mammary tumors and is associated with an aggressive clinical course, even if responds to anti-HER2 treatments [3]. Here, ERBB2 is linked to breast cancer.